“…Eight studies evaluating the relationship between the AMH signalling pathway genotype and ovarian reserve were included for meta-analysis (Cerra et al, 2016;Georgopoulos et al, 2013;Jurczak et al, 2016;Kevenaar et al, 2007bKevenaar et al, , 2008Lazaros et al, 2016;Peluso et al, 2015;Yu et al, 2016 With regard to the association between c.146T>G polymorphism in the AMH gene and ovarian reserve, the metaanalysis of six included studies (Cerra et al, 2016;Jurczak et al, 2016;Kevenaar et al, 2007bKevenaar et al, , 2008Peluso et al, 2015;Yu et al, 2016) showed that no significant difference in serum AMH levels was found between the participants with G/G genotype and carriers of the G/T or T/T genotype (WMD 0.42, 95% CI −0.16 to 0.99) with high heterogeneity (I 2 = 57.6%, P = 0.038) (FIGURE 2A). The European subgroup (Cerra et al, 2016;Jurczak et al, 2016;Kevenaar et al, 2007bKevenaar et al, , 2008 showed a similar result (WMD 0.09, 95% CI −0.43 to 0.62, I 2 = 42.0%). Subgroup analysis in accordance with population showed no significant statistical association in healthy women (Jurczak et al, 2016;Kevenaar et al, 2007b;Yu et al, 2016), infertile women (Cerra et al, 2016;Peluso et al, 2015,) or patients with PCOS (Kevenaar et al, 2008) (WMD 0.66, 95% CI −0.56 to 1.87, I 2 = 75.2%, P = 0.018; WMD 0.47, 95% CI −0.07 to 1.02, I 2 = 0.0%; WMD 0.50, 95% CI −2.19 to 1.19) (FIGURE 2B).…”